BioInvent to Participate in Upcoming Investor Conferences
LUND, SE / ACCESS Newswire / November 9, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
LUND, SE / ACCESS Newswire / November 9, 2026 / BioInvent International AB (“BioInvent”) (STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that representatives from the Company management team will participate in the following upcoming investor conferences this November and December 2026:
BIO-Europe 2026, Cologne, Germany
Format: One-on-one meetings
Date: November 9-11
Aktiespararna Digital Life Science night, Lund, Sweden
Format: Company presentation
Date: November 12
2026 Jefferies Global Healthcare Conference, London, United Kingdom
Format: One-on-one meetings
Date: November 16-19
DNB Carnegie Nordic Healthcare Conference, Oslo, Norway
Format: One-on-one meetings
Date: November 24
Di Investor Summit Life Science, Stockholm, Sweden
Format: Company presentation
Date: December 8
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company’s validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
BioInvent to Participate in Upcoming Investor Conferences
SOURCE: BioInvent International
View the original press release on ACCESS Newswire
Media gallery
